Etamsylate Rompharm 250 mg/2 ml, solution for injection

Therapeutic indications 

In surgery: Prevention and treatment of pre-, per-, or postsurgical capillary haemorrhages in all delicate operations and in those affecting highly vascularised tissues: E.N.T., gynaecology, obstetrics, urology, odontostomatology, ophthalmology, plastic and reconstructive surgery. In paediatrics: Prevention of periventricular haemorrhages in premature babies.

Etamsylate is a synthetic antihaemorrhagic and angioprotective drug acting on the first step of haemostasis (endothelium-platelet interaction). By improving platelet adhesiveness and restoring capillary resistance, it is able to reduce bleeding time and blood losses. Etamsylate has no vasoconstrictor action, it does not influence fibrinolysis nor modify the plasma coagulation factors